This is the 12th school shooting in 2018 - in 32 days. As a dad of 3, no parent should fear sending our kids to our school. The lack of action (or even discussion) from our leaders is unacceptable. Our elected leaders should lead or get out of the way.
These brave girls signed up for a
#COVID19
#vaccine
trial! They weighed the risks and benefits and thoughtfully gave consent. So proud of them and their commitment to science and health. So far, both ladies are feeling good! Thanks
@houfightscovid
#medtwitter
#4thofJulyTips
from a Gyn Onc
1. Get the
#HPV
#vaccine
- it prevents cancer
2. Recommit to fighting for the American right to health care
3. None of us are well until we get those children back to their parents. Cc
@choo_ek
🙌 KEYNOTE826 - longer OVERALL SURVIVAL for patients w/ recurrent
#CervicalCancer
who received pembrolizumab +/- bevacizumab in combination with chemotherapy
#ASCO23
#gyncsm
#ImmunoOnc
💯 STANDARD OF CARE
Stage IV endometrial cancer survivor Julie Dillard got a second chance at life thanks to a clinical trial led by our Dr. Shannon Westin.
Watch her story and learn more about the clinical trial:
@ShannonWestin
#GynCSM
#ESMO23
#EndCancer
🙏❤️💪Thanks
@ASCO
for this incredible honor. It’s my great pleasure to be a volunteer for this awesome society! I am ready to keep working every day for our patients.
🎉 Join us in congratulating the following members on earning the Fellow of ASCO (FASCO) distinction this quarter! We're grateful for your extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about the FASCO distinction:
PRACTICE CHANGE at
#ESMO21
- KEYNOTE-826 - the addition of pembroliuzumab
#Immunotherapy
to standard of care chemotherapy/bevacizumab demonstrates improved progression free and overall survival in advanced/recurrent
#CervicalCancer
. Regardless of PDL1 status or bev use
#gyncsm
.
@ArtAcevedo
with common sense ideas to reduce gun violence in our country. This is his lane- wouldn’t you say
@NRA
?? It’s a public health crisis and law enforcement, physicians, and mental health professionals need to be at the table!
#ThisIsOurLane
@MomsDemand
@Everytown
It is past time our nation convenes a non-partisan, multi-discinplinary commission to establish a comprehensive strategy to address mass-shootings & scourge of daily gun violence. It’s time to demand a deep dive that explores causative factors.
How is it that
@shannonrwatts
of
@MomsDemand
, who is compassionate, gracious, & dedicated to keeping all our kids safer, has fewer followers than Dana Loesch, who is none of those things?
Let’s fix this. Follow her & tag a few friends to do so as well.
🙌So excited to share our study DUO-E/GOG3041/ENGOT-EN10 demonstrated the addition of durvalumab + olaparib or durvalumab alone to chemotherapy/maintenance improves progression free survival in patients w/ advanced/recurrent
#EndometrialCancer
🥰It's a very good day for
#gyncsm
👀this is the FIRST TRIAL to show overall survival benefit in platinum resistant
#OvarianCancer
.
🙌Standard of care is clear!
🧐Get the FOLR1 testing and identify the patients that will benefit from mirvetuximab
#ASCO23
#gyncsm
🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant
#ovariancancer
. Absolutely new standard of care!! 👏
#gyncsm
#ASCO23
So this happened today! Honored to serve our patients
@MDAndersonNews
for 15 years and counting! I love my job and love the opportunity to
#endcancer
as part of the
#oncsurgery
team. I started my fellowship in 2006 and have never looked back! Here's to 15 more
@DrJasonWestin
...
Major Question Answered! The OREO Study demonstrates improved progression free survival w/
#PARPi
maintenance after prior PARP inhibitor in recurrent
#OvarianCancer
- benefit to repeat olaparib maintenance was seen irrespective of
#BRCA
status or HRD testing!
#gyncsm
#ESMO21
Long term update from SOLO1 - upfront
#PARPi
maintenance for pts w/ advanced
#ovariancancer
- incredible long term PFS despite only 2 years treatment. This was consistent across high and low risk subgroups!
#SGOMtg
#gyncsm
Another practice changing study in
#EndometrialCancer
- RUBY demonstrates improved progression free survival for patients treated with IO in combination with chemotherapy
#SGOMtg
#gyncsm
#ImmunoOnc
- Such an exciting time! Now to figure out the choice between these two regimens!
🚨INNOVA-TV 301 study - confirms tisotumab vedotin (tissue factor
#AntibodyDrugConjugate
) is standard of care in recurrent
#CervicalCancer
🙌
🌟Improved OS HR 0.70!!!!
🌟Improved PFS HR 0.67
🌟Improved response 17.8%
vs. investigator-choice chemo
#ESMO2023
#gyncsm
Dr. Makker presenting interim results from KEYNOTE 775 - bottom line - the combo of pembrolizumab and lenvatinib yielded improved PFS and OS for patients w recurrent
#endometrialcancer
compared to chemo. This combo is standard of care!
#SGOMtg
#gyncsm
Checking out the
#ASCO21
plenary session and enjoying the Texas summer! Not too shabby.
@Lymphoma_Doc
and I don’t usually get to hang together this much at
@ASCO
! Next year will be a bit different...
Another
#PARPi
(Rucaparib) is an effective maintenance in women with
#OvarianCancer
after response to upfront chemotherapy! ATHENA-MONO as presented by Dr. Monk at
#ASCO22
🙌Benefit was seen irrespective of biomarker- with greatest benefit in patients with BRCAm/HRD
#gyncsm
📣 Announcing the
#ASCO23
Featured Voices! 🎉 Follow on Twitter, Instagram and/or LinkedIn for a range of expert insights and join the conversation using the official hashtag:
#ASCO23
👉
💊PRIME Study of niraparib as upfront maintenance in all comer
#OvarianCancer
population
🧑🏽🤝🧑🏽Included patients with and without residual disease
📈 PFS improved in all comers with the use of niraparib
#SGOMtg
#SGO2022
#gyncsm
Answering a critical ❓in
#EndometrialCancer
:
✅All pts w/ initial mismatch repair deficiency retained this aberration in recurrence.
‼️9% developed MMRd in the recurrent setting.
👍Great job
@BeccaPrevisMD
- this has potential to guide our testing strategies
#SGOMtg
#gyncsm
🙌Congrats
@Lymphoma_Doc
on serving on the
@ASCO
Association Board of Directors as Treasurer, and as Chair of the Government Relations Committee for
#ASCO23
- what an incredible accomplishment and year of service!
Good points and I’ll address them one by one. The most important is intersectionality. I tend to focus on gender for a number of reasons, but all forces that make things hard for women make it harder when race, ethnicity, gender identity and sexual orientation come into play.
Hi
@DanCrenshawTX
- it would be really super if you would stop posturing and start working with public health experts to actually lead.
#Houston
is now in a
#COVID19
crisis. You are the irresponsible one. We are eagerly anticipating your leadership here!!!
This is such an irresponsible overstatement from our County Judge. Pure and simple fear mongering. It needs to stop. People have figured out what they need to do to remain safe. We have enormous hospital capacity. We can do this.
Come check out our
#ASCO21
presentation tomorrow (6/7) at 7:00AM CST. I will be discussing the results of EFFORT- a randomized trial of adavosertib (WEE1i) alone or in combo w/ olaparib in women w/
#PARPi
resistant
#OvarianCancer
. Many thanks
@asco
and
@MDAndersonNews
!
#gyncsm
Thank you
@GOG
for your support of my research- we are so excited to see this yield benefit to our patients with
#endometrialcancer
I am honored to be in this fight with you!!!
#gyncsm
Congratulations to
@ShannonWestin
from
@MDAndersonNews
who is a
@GOG
Scholar Investigator. "The Scholar Investigator Program has provided me with protected time necessary to focus on protocol development and research," said Westin.
A1: Surgery is an option for patients with recurrent
#ovariancancer
- the AGO DESKTOP III study demonstrates an overall survival benefit in carefully selected women!
#ASCO20
#gyncsm
#SGOatASCO
✅Addition of dostarlimab to chemotherapy in the RUBY trial - PFS consistently improved progression free survival for pts w/
#EndometrialCancer
in the blinded independent central review - the data remain c/w with the NEJM study!
#ASCO23
#gyncsm
#ImmunoOnc
#Immunotherapy
Impressive results from
@KJorgensenMD
. Study of NCDB demonstrated improved overall survival w/ minimally invasive surgery as opposed to open interval tumor reductive surgery in advanced
#OvarianCancer
. The LANCE study will provide prospective data here
#SGOMtg
#oncsurgery
#gyncsm
The scientific community and science advocates can no longer shy away from politics and controversial topics in the face of blatant attempts to silence our work and question its integrity.
#CDC7words
Dr. Sven Mahner discussing the ongoing TRUST trial at
#IGCS2020
. Recruitment is finished - data are expected in 2024! This important study will clarify the role of cytoreductive surgery and neoadjuvant chemotherapy in advanced
#ovariancancer
#gyncsm
#GCAM
Thoughts on the impact of SOLO2 - olaparib maintenance in recurrent
#BRCA
mutant
#ovariancancer
- this randomized trial demonstrated an overall survival benefit in this population - the first trial of
#PARPi
to achieve this!
#ASCO20
#SGOatASCO
#gyncsm
#JIPO
is proud to have Dr. Shannon Westin join the Editorial Board. She is a well-respected physician with expertise in gynecologic onology and drug development at MDACC and Lyndon Baines Johnson Hospital in Houston, TX.
@ShannonWestin
I love educating the public about
#ovariancancer
- knowledge is power. But we must emphasize my last point in this article - seek care from an expert - outcomes are better when women are treated by high volume centers like
@MDAndersonNews
#gyncsm
The combination of tisotumab vedotin (
#ADC
to tissue factor) and carboplatin in frontline
#CervicalCancer
👍 55% response rate, 91% clinical benefit!!!
#ASCO22
#gyncsm
So - why should we Send a Doctor to the House? We have serious problems, and we need serious people to come up with solutions, not partisan games. I running for the right reasons at the right time - but I need your help to win this
#Flippable
seat.
✅Clear benefit of mirvetuxumab soravtansine in recurrent
#OvarianCancer
regardless of number of prior lines of therapy or prior PARPi use. 🤕Only 7% of pts discontinued the agent due to toxicity
#SGOMtg
#SGO2022
#gyncsm
Intraoperative imaging for
#ovariancancer
is an incredible unmet need to allow us to identify active tumor after therapy- pafolacianine sodium allows for identification of folate receptor alpha - which is highly expressed in
#ovariancancer
- quite intriguing!!!
#ASCO21
#gyncsm
Final analysis of the LACC trial- this confirmed the previously presented results that disease free survival and overall survival are worse among women w/
#CervicalCancer
treated w/ minimally invasive surgery as compared to the open. Great work
@pedroramirezMD
#SGOMtg
#gyncsm
The
@ASCO
meeting is completely virtual! It’s the
#SoMe
committee’s time to shine! Honored to be one of the
#ASCO20
featured voices. Follow these amazing colleagues to stay up to date on the latest science!
#gyncsm
I may be tweeting to the choir here 🤭….come check out my
#ASCO22
session on Sunday 6/5 at 11:00am to discuss using
#SocialMedia
to promote your
✍️ Manuscripts
🎤 Presentations
💊 Clinical Trials
🙌 Career!!!!
See you in the
@JCO_ASCO
Publication Lounge!
People of all races, religions and nationalities work at Sanofi every day to improve the lives of people around the world. While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication.
This is a horrendous disease - this is your lungs on
#COVID19
This is why we are going to run out of ICU beds and ventilators if we don't
#FlattenTheCurve
right now. CANCEL EVERYTHING!
“The goal of this study was to understand what’s happening to the tumor before and after treatment and gather translational data to recognize which patients may see survival benefits,” says our
@ShannonWestin
:
#AACR20
#CancerMoonshot
#endcancer